In this issue:
Leukaemia selection
Prognostic CLL model comprising two biomarkers
Idelalisib with R-bendamustine for relapsed/refractory CLL
Blinatumomab vs. chemotherapy for advanced ALL
Long-term outcomes of imatinib for chronic myeloid leukaemia
Long-term outcomes of tretinoin, arsenic trioxide and gemtuzumab for APL
Lymphoma selection
Ibrutinib in relapsed/ refractory MZL
Response quality and outcomes with VR-CAP vs. R-CHOP for newly diagnosed MCL
Rituximab and/or chlorambucil for mucosa-associated lymphoid tissue lymphoma
PDUS-guided biopsy for characterising lymphadenopathies in suspected lymphoma
BEACOPPesc ±rituximab for PET-2 advanced Hodgkin’s lymphoma
Please login below to download this issue (PDF)